首页
Recombinant Human IL-15 Protein, CF
Recombinant Human IL-15 Protein, CF
1/3

Recombinant Human IL-15 Protein, CF

分享
品牌： R&D Systems
pdf 下载产品说明书
pdf 下载SDS
用小程序，查商品更便捷
收藏
对比对比
咨询咨询
    产品介绍
    产品信息

    Scientific Data

    SEC-MALS View Larger

    Recombinant Human IL-15 (Catalog # BT-015) has a molecular weight (MW) of 13.2 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer.

    Bioactivity View Larger

    Recombinant Human IL-15 (Catalog # BT-015) stimulates cell proliferation in the MO7e human megakaryocytic leukemic cell line. The ED50 for this effect is 0.300-2.60 ng/mL.

    SDS-PAGE View Larger

    2 μg/lane of Recombinant Human IL‑15 Protein (Catalog # BT-015) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 9 kDa.

    Carrier Free

    What does CF mean?

    CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

    What formulation is right for me?

    In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

    BT-015

    FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
    ReconstitutionReconstitute at 100-500 μg/mL in PBS.
    ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

    Recombinant Human IL-15 Protein, CF Summary

    Product Specifications

    Purity
    >97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
    Endotoxin Level
    <0.10 EU per 1 μg of the protein by the LAL method.
    Activity
    Measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells. The ED50 for this effect is 0.300-2.60 ng/mL.
    Source
    E. coli-derived human IL-15 protein
    Asn49-Ser162
    Accession #
    P40933.1
    N-terminal Sequence
    Analysis
    Asn49
    Predicted Molecular Mass
    13 kDa
    SDS-PAGE
    9 kDa, under reducing conditions.
    背景
    别名
    IL15,IL-15,IL-15MGC9721,interleukin 15,interleukin-15,Interleukin 15
    背景

    Background: IL-15

    Interleukin 15 (IL-15) is a widely expressed 14 kDa cytokine that is structurally and functionally related to IL-2 and plays an important role in many immunological diseases (1, 2). Mature human IL-15 shares 70% amino acid sequence identity with mouse and rat IL-15. Alternative splicing generates isoforms of IL-15 with either a long or short signal peptide (LSP or SSP), and the SSP isoform is retained intracellularly (3). IL-15 binds with high affinity to IL-15 R alpha (4). It binds with lower affinity to a complex of IL-2 R beta and the common gamma chain ( gamma c) which are also subunits of the IL-2 receptor complex (5). IL-15 associates with IL-15 R alpha in the endoplasmic reticulum, and this complex is expressed on the cell surface (6). 

    The dominant mechanism of IL-15 action is known as transpresentation in which IL-15 and IL-15 R alpha are coordinately expressed on the surface of one cell and interact with complexes of IL-2 R beta / gamma c on adjacent cells (7). This enables cells to respond to IL-15 even if they do not express IL-15 R alpha (6). In human and mouse, soluble IL-15-binding forms of IL-15 R alpha can be generated by proteolytic shedding and bind up nearly all the IL-15 in circulation (8-10). Soluble IL-15 R alpha functions as an inhibitor that limits IL-15 action (4, 9). Ligation of membrane-associated IL-15/IL-15 R alpha complexes also induces reverse signaling that promotes activation of the IL-15/IL-15 R alpha expressing cells (11). IL-15 induces or enhances the differentiation, maintenance, or activation of multiple T cell subsets including NK, NKT, Th17, Treg, and CD8+ memory cells (12 - 16). An important component of these functions is the ability of IL‑15 to induce dendritic cell differentiation and inflammatory activation (11, 14). IL-15 exhibits anti-tumor activity independent of its actions on NK cells or CD8+ T cells (17). It also inhibits the deposition of lipid in adipocytes, and its circulating levels are decreased in obesity (18). 

    Immunotherapy treatment with recombinant IL-15 has the advantage of not stimulating Treg cells like IL-2 does but has the drawback of associated toxicity at higher doses. This has led to increased investigation on mitigating IL-15 toxicity and combination immunotherapy approaches using immune checkpoint inhibitors (19, 20). Preclinical and early clinical studies have shown the potential of also using IL-15 in combination with cancer vaccines to improve their anti-tumor response (20). IL-15 can also be used for the preconditioning of CAR T cells or for engineering cells to express IL-15 in vivo. Adoptive cell transfer of NK cells engineered to express CD19 and IL-15 were well tolerated in patients with CD19-positive cancers (20). 

    IL-15 can be used in combination with other cytokines like IL-21 to increase the efficiency of NK cell expansion and maturation in stem cell culture protocols (21). The combination of IL-15 with IL-7 also promotes expansion of early-differentiated CD8+ T cells in culture with the added benefit of decreasing Treg cell generation, unlike IL-2, for adoptive cell transfer in cancer immunotherapy (22). GMP IL-7 and GMP IL-15 are commonly used in combination for ex vivo expansion of T cells for cellular therapies.

    References
    1. De Sabatino, A. et al. (2011) Cytokine Growth Factor Rev. 22:19.
    2. Grabstein, K. et al. (1994) Science 264:965.
    3. Tagaya, Y. et al. (1997) Proc. Natl. Acad. Sci. USA 94:14444.
    4. Giri, J.G. et al. (1995) EMBO J. 14:3654.
    5. Giri, J. et al. (1994) EMBO J. 13:2822.
    6. Dubois, S. et al. (2002) Immunity 17:537.
    7. Castillo, E.F. and K.S. Schluns (2012) Cytokine 59:479.
    8. Budagian, V. et al. (2004) J. Biol. Chem. 279:40368.
    9. Mortier, E. et al. (2004) J. Immunol. 173:1681.
    10. Bergamaschi, C. et al. (2012) Blood 120:e1.
    11. Budagian, V. et al. (2004) J. Biol. Chem. 279:42192.
    12. Mortier, E. et al. (2003) J. Exp. Med. 205:1213.
    13. Gordy, L.E. et al. (2011) J. Immunol. 187:6335.
    14. Harris, K.M. (2011) J. Leukoc. Biol. 90:727.
    15. Xia, J. et al. (2010) Clin. Immunol. 134:130.
    16. Schluns, K.S. et al. (2002) J. Immunol. 168:4827.
    17. Davies, E. et al. (2010) J. Leukoc. Biol. 88:529.
    18. Barra, N.G. et al. (2010) Obesity 18:1601.
    19. Xue, D. et al. (2021) Antib Ther. 4:123.
    20. Wolfarth, A.A. et al. (2022) Immune Netw. 22:e5.
    21. Oberoi, P. et al. (2020). Cells. 9:811.
    22. Chamucero-Millares, J.A. et al. (2021) Cellular Immunol. 360:104257.
    Long Name
    Interleukin 15
    Entrez Gene IDs
    3600 (Human); 16168 (Mouse); 25670 (Rat); 102119613 (Cynomolgus Monkey); 493682 (Feline)
    Alternate Names
    IL15; IL-15; IL-15MGC9721; interleukin 15; interleukin-15
    研究领域
    声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。
    货号：
    BT-015-010
    一键复制
    询价
    1MG
    10ug
    25ug
    100ug
    250ug
    选择数量
    当前规格1件起购 
    配送至
    预计2-3周送达，快递: 免运费，若需干冰额外收费
    询价 大包装询价